28.7 C
Monday, February 26, 2024
HomeCovid-19COVID Pill Near 90% Effective In Clinical Trials – Pfizer

COVID Pill Near 90% Effective In Clinical Trials – Pfizer


Related stories

Senseless Movie Is Better Than Pornography” – Shatana Slams Martha Ankomah

Philanthropist and female songstress, Shatana has replied famed actress,...

LBO Featherweight Champion “Ashanti Warrior” Presents Title to Otumfuo Osei Tutu II

On February 18, 2024, LBO Featherweight Champion Stanley Nyantakyi gladly presented his title to Monarch Otumfuo Osei Tutu II at the year's second Akwasidae celebration. Nyantakyi, also known as the Asante Warrior, retained his unbeaten record by knocking out Togo's Komlangan Hounkpatin in his first international fight in Accra on February 3, 2024, to capture the LBO Featherweight title. Accompanied by his management team, Osibo Boxing Management and Promotion, Nyantakyi requested permission to incorporate the return leg of his bout into activities planned for Otumfuo's Silver Jubilee in the following months. The match will be held in Kumasi. Born and bred in Kumasi, Nyantakyi migrated to...


The National youth Wing of the governing New Patriotic...

Election 2024: Nigerians advised not to be involved in Ghana Politics

The Nigerian King of Adoteiman and Amranhia at the...

Kingdom FM’s Real Aj Wins Radio Personality of Year Award

Television presenter, Joyce Afum, popularly known in the showbiz...

Pfizer Inc has said the final analysis of its antiviral COVID-19 pill showed close to 90 percent efficacy in preventing hospitalizations and deaths in high-risk patients with recent lab data suggesting the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.

The US drug maker’s remarks came on Tuesday after it said last month the oral medicine was about 89 percent effective in preventing hospitalizations or deaths when compared with placebo based on interim results in about 1,200 people.

The data disclosed on Tuesday includes an additional 1,000 people.

Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.

The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after the onset of symptoms.

If authorised, the treatment will be sold as Paxlovid.

Pfizer also released early data from a second clinical trial showing that the treatment reduced hospitalizations by approximately 70 percent in about 600 standard-risk adults.

“It’s a stunning outcome,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.

“We’re talking about a staggering number of lives saved and hospitalisations prevented. If you deploy this quickly after infection, we are likely to reduce transmission dramatically,” Dolsten added.

There are currently no oral antiviral treatments for COVID-9 authorised in the United States.

Rival Merck & Co has asked for emergency use authorisation of its antiviral pill molnupiravir. But that drug reduced hospitalisations and deaths in its clinical trial of high-risk patients by only about 30 percent.

Pfizer shares fell 0.8 percent to $54.75 in trading before the bell, while Merck shares were flat at $72.69.

Dolsten said recent laboratory testing showed that the activity against the protease of the Omicron variant is as “good as basically any SARS-COV-2 variant of concern”.

Ready to ship

The company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.

Dolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher.

Current vaccines appear to be less effective at preventing infection with Omicron.

Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech, has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).

However, Dolsten said for next year he expects the drug would be mainly produced by Pfizer.

The US government has already secured 10 million courses of the Pfizer drug for $5.29bn.


- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories